The European Commission has approved a new 7.2 mg weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity, providing an additional therapeutic option for those requiring greater weight loss.

The European Commission has approved a 7.2 mg once-weekly injectable dose of semaglutide for adults living with obesity, following clinical trials that showed up to a 21% reduction in body weight.

The World Anti-Doping Agency (WADA) is investigating whether popular weight-loss injections, such as semaglutide, should be added to the list of banned substances for the 2028 Olympic Games.

Indian pharmaceutical companies Eris Lifesciences and Natco Pharma have entered into an agreement concerning the drug Semaglutide.